Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

110.33 -1.37 (-1.23%)
Official Closing Price Updated: 7:00 PM EDT, Jul 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,351,098
Open 112.04
Bid (Size) 105.00 (1)
Ask (Size) 112.50 (1)
Prev. Close 111.70
Today's Range 110.23 - 112.04
52wk Range 92.19 - 112.48
Shares Outstanding N/A
Dividend Yield 3.14%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Spinoff Stocks You Should Buy Now: July 2024
Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early. 
Via InvestorPlace
Netflix, Goldman Sachs, J&J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years
Following a lackluster big bank earnings, market participants now turn their attention to the unfolding week, expecting the trend to reverse. 
Via Benzinga

Performance

YTD
+9.24%
+9.24%
1 Month
+5.15%
+5.15%
3 Month
+16.86%
+16.86%
6 Month
+2.45%
+2.45%
1 Year
+11.51%
+11.51%

More News

Read More
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
Via InvestorPlace
Is NYSE:NVS a Good Fit for Dividend Investing?
Via Chartmill
Exploring NYSE:NVS's dividend characteristics.
Via Chartmill
Balancing Dividends and Fundamentals: The Case of NYSE:NVS.
Via Chartmill
3 Healthcare Stocks Injecting AI for Big Gains
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Novartis Stock Generating Improved Relative Strength
Via Investor's Business Daily
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Via Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Via InvestorPlace
Mississippi Judge Upholds State Law Mandating Drug Discounts for Low-Income Patients
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Superlab Suisse opens state-of-the-art facility in Basel, fostering new spaces for scientific breakthroughs
Via News Direct
Novartis Stock Just Below Innovative Drugmaker's All-Time High; Gets Key Rating Upgrade
Via Investor's Business Daily
Nestle Carefully Targets Weight-Loss Drug Users with New Food Line
Via Benzinga
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Via Benzinga
What's Going On With Neurological Disease Focused Trevena On Thursday?
Via Benzinga
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Via InvestorPlace
3 Crazy Good Stocks to Buy With $500 Right Now
Via InvestorPlace
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Via Benzinga
Leigh Burgess, CEO & Founder Bold Industries Group, Announces Pre-Sale of New Book: Be BOLD Today
Via Get News
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024
Via InvestorPlace
Novartis Sues to Block Maryland's New Drug Discount Law
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novartis' Oral Drug For Chronic Skin Disease Candidate Shows Efficacy, Long-term Safety
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.